IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers. Visit www.isoplexis.com to learn more.